Published in J Appl Microbiol on September 01, 2006
Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain. Sci Rep (2012) 0.96
Bacteria in Cancer Therapy: Renaissance of an Old Concept. Int J Microbiol (2016) 0.95
Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. Am J Vet Res (2012) 0.95
Identification of tumor-specific Salmonella Typhimurium promoters and their regulatory logic. Nucleic Acids Res (2011) 0.88
Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β. Theranostics (2015) 0.82
Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. Microb Biotechnol (2017) 0.79
Tumor-targeting bacterial therapy: A potential treatment for oral cancer (Review). Oncol Lett (2014) 0.76
Strains, Mechanism, and Perspective: Salmonella-Based Cancer Therapy. Int J Microbiol (2016) 0.76
Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress. Cancers (Basel) (2016) 0.75
Effect of Heat-Inactivated Clostridium sporogenes and Its Conditioned Media on 3-Dimensional Colorectal Cancer Cell Models. Sci Rep (2015) 0.75
'Obligate' anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice. Oncol Lett (2016) 0.75
Composing a Tumor Specific Bacterial Promoter. PLoS One (2016) 0.75
The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol (1996) 1.69
Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS (1998) 1.52
Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Virology (1992) 1.38
Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer (2006) 1.19
Effect of clavulanic acid on the minimum inhibitory concentration of benzylpenicillin, ampicillin, carbenicillin, or cephalothin against clinical isolates resistant to beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 1.19
The nucleotide sequences of the 5 S rRNAs of seven molds and a yeast and their use in studying ascomycete phylogeny. Nucleic Acids Res (1984) 1.19
Induced fusion of fungal protoplasts following treatment with polyethylene glycol. J Gen Microbiol (1976) 1.14
Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther (2001) 1.12
Conditions for induced fusion of fungal protoplasts in polyethylene glycol solutions. Arch Microbiol (1975) 1.12
The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res (1996) 1.06
Twin-arginine translocation pathway in Streptomyces lividans. J Bacteriol (2001) 1.05
The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev (2000) 1.05
Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther (2001) 1.05
Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer (2000) 1.04
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol (2001) 1.04
Formation and regeneration of Penicillium chrysogenum protoplasts. Arch Microbiol (1974) 1.04
Tumor-specific gene delivery using genetically engineered bacteria. Curr Gene Ther (2003) 1.00
Streptomyces lividans as host for heterologous protein production. FEMS Microbiol Lett (1993) 0.98
Site-specific integration of bacteriophage VWB genome into Streptomyces venezuelae and construction of a VWB-based integrative vector. Microbiology (1998) 0.97
Efficient secretion of biologically active mouse tumor necrosis factor alpha by Streptomyces lividans. Gene (1994) 0.97
Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus. J Gen Virol (1992) 0.95
Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors. Mol Pharmacol (1993) 0.95
Fidelity analysis of HIV-1 reverse transcriptase mutants with an altered amino-acid sequence at residues Leu74, Glu89, Tyr115, Tyr183 and Met184. Eur J Biochem (2000) 0.94
Evaluation of a novel subtilisin inhibitor gene and mutant derivatives for the expression and secretion of mouse tumor necrosis factor alpha by Streptomyces lividans. Appl Environ Microbiol (1997) 0.93
Leaf metallome preserved over 50 million years. Metallomics (2014) 0.92
Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. Appl Environ Microbiol (1999) 0.92
Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res (1996) 0.91
Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe (1998) 0.91
Protein secretion biotechnology using Streptomyces lividans: large-scale production of functional trimeric tumor necrosis factor alpha. Biotechnol Bioeng (2001) 0.91
Efficient isolation of total RNA from Clostridium without DNA contamination. J Microbiol Methods (2001) 0.90
Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours. Br J Cancer (2003) 0.90
The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. Radiat Res (2001) 0.90
Antifungal and antibacterial activities of diarylamidine derivatives. Antimicrob Agents Chemother (1980) 0.88
Complete genomic nucleotide sequence and analysis of the temperate bacteriophage VWB. Virology (2005) 0.88
Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1. AIDS Res Hum Retroviruses (1998) 0.88
Four genes encoding different type I signal peptidases are organized in a cluster in Streptomyces lividans TK21. Microbiology (1999) 0.87
Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. Anticancer Res (2001) 0.87
Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters. Appl Environ Microbiol (2001) 0.86
Improved PCR-based method for the direct screening of Streptomyces transformants. J Microbiol Methods (2003) 0.85
Molecular characterization of a novel subtilisin inhibitor protein produced by Streptomyces venezuelae CBS762.70. DNA Seq (1998) 0.84
Morphological and molecular characterization of several actinophages isolated from soil which lyse Streptomyces cattleya or S. venezuelae. J Gen Microbiol (1984) 0.84
In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys (2001) 0.84
Modifications of Streptomyces signal peptides and their effects on protein production and secretion. FEMS Microbiol Lett (1998) 0.83
Clostridium spores for tumor-specific drug delivery. Anticancer Drugs (2002) 0.83
Influence of charge variation in the Streptomyces venezuelae alpha-amylase signal peptide on heterologous protein production by Streptomyces lividans. Appl Microbiol Biotechnol (1998) 0.82
Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions. Ann Oncol (2003) 0.81
Catalytic activity and stability of hammerhead ribozymes containing 2'-acetamido-2'-deoxyribonucleosides. Biochem Biophys Res Commun (1995) 0.81
Isolation of high quality RNA from Streptomyces. J Microbiol Methods (2004) 0.81
Optimum conditions for efficient transformation of Streptomyces venezuelae protoplasts. Appl Microbiol Biotechnol (1990) 0.80
Analysis of the open reading frames of the main capsid proteins of actinophage VWB. Arch Virol (1995) 0.79
Functional analysis of the Streptomyces lividans type I signal peptidases. Arch Microbiol (2001) 0.79
Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect Prev (2001) 0.79
Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrob Agents Chemother (1997) 0.79
Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA. Biochem J (1996) 0.79
A restriction endonuclease map of Streptomyces phage VWB. Mol Gen Genet (1985) 0.79
The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase. Int J Radiat Biol (2000) 0.78
The Sip(Sli) gene of Streptomyces lividans TK24 specifies an unusual signal peptidase with a putative C-terminal transmembrane anchor. DNA Seq (1998) 0.76
Further biological and molecular characterization of actinophage VWB. J Gen Microbiol (1990) 0.76
Membrane topology of the Streptomyces lividans type I signal peptidases. J Bacteriol (2001) 0.76
Determination of the packaging capacity of bacteriophage VWB. J Bacteriol (1990) 0.75
Codon adjustment to maximise heterologous gene expression in Streptomyces lividans can lead to decreased mRNA stability and protein yield. Mol Gen Genet (1996) 0.75
A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1. J Virol Methods (1996) 0.75
Protoplasts of filamentous fungi in genetics and metabolite production. Experientia Suppl (1983) 0.75
[Intra- and interspecific protoplast fusion in fungi: a method for industrial strain improvement? (author's transl)]. J Pharm Belg (1979) 0.75
Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors of different sizes. Cancer Invest (2001) 0.75